Volume 26, Issue 125, July 2022

Postoperative outcome of pancreaticoduodenectomy for pancreatic ductal adenocarcinoma and predictors of 1st year mortality

Sayed Shaker Shaeir^1♦, Fouad Abdelshaheed¹, Ahmed Elsebaiy¹, Mohamed Emam Sobeih², Eman Desoky³, Ahmed Shaaban Owis⁴, Mahitab Ibrahim Eltohamy⁵, Haitham Fekry Othman¹

¹Department of Surgical Oncology, National Cancer Institute, Cairo University, 11796, Cairo, Egypt
²Department of Medical Oncology, National Cancer Institute, Cairo University, 11796, Cairo, Egypt
³Department of Cancer Epidemiology and Biostatistics, National Cancer Institute, 11796, Cairo University, Cairo, Egypt
⁴Department of Radiology, National Cancer Institute, 11796, Cairo University, Cairo, Egypt
⁵Department of Pathology, National Cancer Institute11796, Cairo University, Cairo, Egypt

^♦Corresponding author
Department of Surgical Oncology, National Cancer Institute, Cairo University, Fom El Khalig Square, 11796, Cairo, Egypt

ABSTRACT

Background: Due to late detection, a low percentage of resectable malignancies, and resistance to systemic therapy, pancreatic ductal adenocarcinoma (PDAC) has the poorest outcome of all pancreatic cancers. The basis of contemporary multimodal therapies aimed at long-term survival is complete lesion excision. Postoperative complications are common consequences following pancreaticoduodenectomy (PD). Objective: To investigate the outcome and factors contributing to the 1st year survival after Whipple’s procedure for pancreatic ductal adenocarcinoma. Patients and Methods: Between January 2020 and December 2021, all patients identified with pancreatic ductal adenocarcinoma (61 individuals) who had Whipple's surgery in the surgical department at the National Cancer Institute were included in this retrospective cohort analysis. Results: Wound infection (49.2%), followed by pancreatic leak (41.7%) were the most prevalent complications among the 61 patients who received PD. The 1styear survival rate was 77% (47/61). In multivariate assessment postoperative pancreatic fistula and adjuvant treatment were independent predictors of 1styear survival. Conclusion: In multimodally managed patients following curative PDAC surgery, individuals who acquired a postoperative pancreatic fistula and did not get adjuvant therapy had greater 1st year death rates.

Keywords: Pancreaticoduodenectomy; Pancreatic tumor survival; Ductal adenocarcinoma

Medical Science, 2022, 26, ms290e2294

PDF

DOI: https://doi.org/10.54905/disssi/v26i125/ms290e2294

Published: 20 July 2022